2226-5988 2686-6749 Клиническая и экспериментальная морфология Clinical and Experimental Morphology ООО "Группа МДВ" 10.31088/CEM2023.12.4.5-13 Метаболизм холестерина при ревматических заболеваниях Cholesterol metabolism in rheumatic diseases Богатырева Анастасия Ильинична Богатырева Анастасия Ильинична Bogatyreva Anastasia I. cem.journal@mail.ru 0000-0002-1188-194 Маркина Юлия Владимировна Маркина Юлия Владимировна Markina Yuliya V. yu.v.markina@gmail.com 0000-0002-3781-6340 Толстик Таисия Владимировна Толстик Таисия Владимировна Tolstik Taisiya V. cem.journal@mail.ru 0000-0002-2897-4777 Кириченко Татьяна Владимировна Кириченко Татьяна Владимировна Kirichenko Tatiana V. cem.journal@mail.ru 0000-0002-2899-9202 Маркин Александр Михайлович Маркин Александр Михайлович Markin Alexander M. cem.journal@mail.ru 0000-0002-6649-7924 Научно-исследовательский институт морфологии человека имени академика А.П. Авцына ФГБНУ «Российский научный центр хирургии имени академика Б.В. Петровского» (Москва, Россия) Avtsyn Research Institute of Human Morphology of FSBSI “Petrovsky National Research Centre of Surgery” (Moscow, Russia) 25 12 2023 2023 12 4 5 13 12 04 2023 20 06 2023 11 05 2023

Дислипидемия является традиционным фактором риска атеросклероза и наблюдается при большинстве ревматических заболеваний, что обусловливает высокий сердечно-сосудистый риск у пациентов с аутоиммунной патологией. В обзоре рассмотрены основные аспекты метаболизма холестерина при аутоиммунных ревматических заболеваниях, связанные с дисфункцией моноци-тов и макрофагов. Изучение патогенетических механизмов обмена холестерина при хронических воспалительных заболеваниях имеет важное фундаментальное и клиническое значение, поскольку дает возможность разрабатывать новые диагностические алгоритмы и терапевтические подходы для снижения сердечно-сосудистого риска у данной категории пациентов, а также может стать основой для создания альтернативных стратегий воздействия на функции иммунных клеток.

Dyslipidemia is a conventional risk factor for atherosclerosis and is observed in most rheumatic diseases, which leads to a high cardiovascular risk in patients with autoimmune pathology. The review consi-ders the main aspects of cholesterol metabolism associated with dysfunction of monocytes and macrophages in autoimmune rheumatic diseases. The study of the pathogenetic mechanisms of cholesterol metabolism in chronic inammatory diseases is of great fundamental and clinical importance, since it allows the development of new diagnostic algorithms and therapeutic approaches to reduce cardiovascular risks in these patients. Moreover, it can be used for creating alternative strategies to modify the functions of the immune system.

 Ключевые слова метаболизм холестерина дислипидемия макрофаги воспаление аутоиммунные заболевания Keywords cholesterol metabolism dyslipidemia macrophages inflammation autoimmune diseases Исследование выполнено в рамках государственного задания Научно-исследовательского института морфологии человека имени академика А.П. Авцына ФГБНУ «Российский научный центр хирургии имени академика Б.В. Петровского» (№ 123030700024-4). The study was carried out within the framework of State Assignment to Avtsyn Research Institute of Human Morphology of FSBSI “Petrovsky National Research Centre of Surgery” (No. 123030700024-4). Schiffenbauer A, Miller FW. Noninfectious environmental agents and autoimmunity. In: NR Rose, IR Mackay (eds.) The Autoimmune Diseases. 6th ed. Academic Press, 2020. P. 345–62. DOI: 10.1016/B978-0-12-812102-3.00020-8. Vargas-Uricoechea H. Molecular mechanisms in autoimmune thyroid disease. Cells. 2023;12(6):918. DOI: 10.3390/cells12060918. Simon TA, Kawabata H, Ray N, Baheti A, Suissa S, Esdaile JM.Prevalence of co-existing autoimmune disease in rheumatoid arthritis: a cross-sectional study. Adv Ther. 2017;34(11):2481–90. DOI: 10.1007/s12325-017-0627-3. Alexandropoulou I, Grammatikopoulou MG, Gkouskou KK, Pritsa AA, Vassilakou T, Rigopoulou E et al. Ceramides in autoimmune rheumatic diseases: existing evidence and therapeutic considerations for diet as an anticeramide treatment. Nutrients. 2023;15(1):229. DOI: 10.3390/nu15010229. Rhoads JP, Major AS, Rathmell JC. Fine tuning of im-munometabolism for the treatment of rheumatic diseases. Nat Rev Rheumatol. 2017;13(5):313–20. DOI: 10.1038/nrrheum.2017.54. Ruscitti P, Di Muzio C, Conforti A, Di Cola I, Pavlych V, Navarini L et al. Cardiometabolic multimorbidity may identify a more severe subset of rheumatoid arthritis, results from a “real-life” study. Medicine (Baltimore). 2023;102(14):e33362. DOI: 10.1097/MD.0000000000033362. Михалева Л.М., Коноплянников А.Г., Кудрявцева Я.Ю., Оленев А.С., Грачева Н.А., Бирюков А.Е. и др. Экстрагениталь-ная неинфекционная патология в структуре материнской смертности г. Москвы. Клиническая и экспериментальная морфология. 2021;10(2):21–31. DOI: 10.31088/CEM2021.10.2.21-31. Mikhaleva LM, Konoplyannikov AG, Kudryavtseva YY, Olenev AS, Gracheva NA, Biryukov AE et al. Extragenital noninfec-tious pathology in the maternal mortality structure in Moscow. Clinical and experimental morphology. 2021;10(2):21–31 (In Russ.). DOI: 10.31088/CEM2021.10.2.21-31. Mahmoud NF, Allam NM, Omara II, Fouda HA. Efficacy of Siwan traditional therapy on erythrocyte sedimentation rate, lipid profile, and atherogenic index as cardiac risk factors related to rheumatoid arthritis. Medicina (Kaunas). 2022;59(1):54. DOI: 10.3390/medicina59010054. Libby P. The changing Nature of atherosclerosis: what we thought we knew, what we think we know, and what we have to learn. Eur Heart J. 2021;42(47):4781–2. DOI: 10.1093/eurheartj/ehab438. Маркин А.М., Маркина Ю.В., Сухоруков В.Н., Хайлов А.М., Орехов А.Н. Роль физических нагрузок в развитии атеро-склеротических поражений сосудистой стенки. Клиниче-ская и экспериментальная морфология. 2019;8(4):25–31. DOI: 10.31088/CEM2019.8.4.25-31. Markin AM, Markina YuV, Sukhorukov VN, Khaylov AM, Orekhov AN. The role of physical activity in the development of atherosclerotic lesions of the vascular wall. Clinical and experimental morphology. 2019;8(4):25–31 (In Russ.). DOI: 10.31088/CEM2019.8.4.25-31. Robinson G, Pineda-Torra I, Ciurtin C, Jury EC. Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies. J Clin Invest. 2022;132(2):e148552. DOI: 10.1172/JCI148552. Venetsanopoulou AI, Kalpourtzi N, Alamanos Y, Gavana M, Vantarakis A, Hadjichristodoulou C et al. Prevalence of rheumatoid arthritis in Greece: results from the national health ex-amination survey EMENO. Rheumatol Int. 2023;43(7):1349–55. DOI: 10.1007/s00296-023-05316-3. Fazeli MS, Khaychuk V, Wittstock K, Breznen B, Crocket G, Pourrahmat MM et al. Cardiovascular disease in rheumatoid arthritis: risk factors, autoantibodies, and the effect of antirheumatic therapies. Clin Med Insights Arthritis Musculoskelet Disord. 2021;14:11795441211028751. DOI: 10.1177/11795441211028751. Yang Y, Liu K, Liu M, Zhang H, Guo M. EZH2: Its regulation and roles in immune disturbance of SLE. Front Pharmacol. 2022;13:1002741. DOI: 10.3389/fphar.2022.1002741. Ebrahimiyan H, Mostafaei S, Aslani S, Faezi ST, Farhadi E, Jamshidi A et al. Association between complement gene polymorphisms and systemic lupus erythematosus: a systematic review and meta-analysis. Clin Exp Med. 2022;22(3):427–38. DOI: 10.1007/s10238-021-00758-0. Kobiyama K, Ley K. Atherosclerosis: a chronic inflammatory disease with an autoimmune component. Circ Res. 2018;123(10): 1118–20. DOI: 10.1161/CIRCRESAHA.118.313816. Thakur M, Evans B, Schindewolf M, Baumgartner I, Döring Y. Neutrophil extracellular traps affecting cardiovascular health in infectious and inflammatory diseases. Cells. 2021;10(7):1689. DOI: 10.3390/cells10071689. Nordestgaard BG. Triglyceriderich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118(4):547–63. DOI: 10.1161/CIRCRESAHA.115.306249. Gulshan K. Crosstalk between cholesterol, ABC transporters, and PIP2 in inflammation and atherosclerosis. Adv Exp Med Biol. 2023;1422:353–77. DOI: 10.1007/978-3-031-21547-6_13. Goldberg IJ, Reue K, Abumrad NA, Bickel PE, Cohen S, Fisher EA et al. Deciphering the role of lipid droplets in cardio-vascular disease: a report from the 2017 national heart, lung, and blood institute workshop. Circulation. 2018;138(3):305–15. DOI: 10.1161/CIRCULATIONAHA.118.033704. Maja M, Tyteca D. Alteration of cholesterol distribution at the plasma membrane of cancer cells: from evidence to pathophysiological implication and promising therapy strategy. Front Physiol. 2022;13:999883. DOI: 10.3389/fphys.2022.999883. Liu B, Ma Y, Huang Y, Liu Z, Ruan Q, Qi Y. Inhibition of hu-man cytomegalovirus particle maturation by activation of liver X receptor. Front Microbiol. 2022;13:846386. DOI: 10.3389/fmicb.2022.846386. Juhl AD, Wüstner D. Pathways and mechanisms of cellular cholesterol efflux-insight from imaging. Front Cell Dev Biol. 2022;10:834408. DOI: 10.3389/fcell.2022.834408. Endo Y, Fujita M, Ikewaki K. HDL functions-current status and future perspectives. Biomolecules. 2023;13(1):105. DOI: 10.3390/biom13010105. Frambach SJCM, de Haas R, Smeitink JAM, Rongen GA, Russel FGM, Schirris TJJ. Brothers in arms: ABCA1- and ABCG1-mediated cholesterol efflux as promising targets in cardiovascular disease treatment. Pharmacol Rev. 2020;72(1):152–90. DOI: 10.1124/pr.119.017897. Chiang JYL, Ferrell JM, Wu Y, Boehme S. Bile acid and chole-sterol metabolism in atherosclerotic cardiovascular disease and therapy. Cardiol Plus. 2020;5(4):159–70. PMID: 34350368. Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport: basic mechanisms and their roles in vascular health and disease. Circ Res. 2019;124(10):1505–18. DOI: 10.1161/CIRCRESAHA.119.312617. Li Y, Wu S, Zhao X, Hao S, Li F, Wang Y et al. Key events in cancer: dysregulation of SREBPs. Front Pharmacol. 2023;14:1130747. DOI: 10.3389/fphar.2023.1130747. Madison BB. Srebp2: a master regulator of sterol and fatty acid synthesis. J Lipid Res. 2016;57(3):333–5. DOI: 10.1194/jlr.C066712. Rayner KJ, Suárez Y, Dávalos A, Parathath S, Fitzgerald ML, Tamehiro N et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328(5985):1570–3. DOI: 10.1126/science.1189862. Le F, Lou HY, Wang QJ, Wang N, Wang LY, Li LJ et al. In-creased hepatic INSIG-SCAP-SREBP expression is associated with cholesterol metabolism disorder in assisted reproductive technology-conceived aged mice. Reprod Toxicol. 2019;84:9–17. DOI: 10.1016/j.reprotox.2018.12.003. Lee JH, Lee SH, Lee EH, Cho JY, Song DK, Lee YJ et al. SCAP deficiency facilitates obesity and insulin resistance through shifting adipose tissue macrophage polarization. J Adv Res. 2023;45:1–13. DOI: 10.1016/j.jare.2022.05.013. Miyata S, Kodaka M, Kikuchi A, Matsunaga Y, Shoji K, Kuan YC et al. Sulforaphane suppresses the activity of sterol regulatory element-binding proteins (SREBPs) by promoting SREBP precursor degradation. Sci Rep. 2022;12(1):8715. DOI: 10.1038/s41598-022-12347-6. He C, Hu X, Weston TA, Jung RS, Sandhu J, Huang S et al.Macrophages release plasma membrane-derived particles rich in accessible cholesterol. Proc Natl Acad Sci USA. 2018;115(36):E8499–508. DOI: 10.1073/pnas.1810724115. Dergunov AD, Baserova VB. Different pathways of cellular cholesterol efflux. Cell Biochem Biophys. 2022;80(3):471–81. DOI: 10.1007/s12013-022-01081-5. He C, Jiang H, Song W, Riezman H, Tontonoz P, Weston TA et al. Cultured macrophages transfer surplus cholesterol into adjacent cells in the absence of serum or high-density lipoproteins. Proc Natl Acad Sci USA. 2020;117(19):10476–83. DOI: 10.1073/pnas.1922879117. Radulovic M, Wenzel EM, Gilani S, Holland LK, Lystad AH, Phuyal S et al. Cholesterol transfer via endoplasmic reticulum contacts mediates lysosome damage repair. EMBO J. 2022;41(24):e112677. DOI: 10.15252/embj.2022112677. Kentala H, WeberBoyvat M, Olkkonen VM. OSBP-related protein family: mediators of lipid transport and signaling at membrane contact sites. Int Rev Cell Mol Biol. 2016;321:299–340. DOI: 10.1016/bs.ircmb.2015.09.006. Teupser D, Kretzschmar D, Tennert C, Burkhardt R, Wilfert W, Fengler D et al. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol. 2008;28(11):2009–15. DOI: 10.1161/ATVBAHA.108.175257. Waddington KE, Robinson GA, RubioCuesta B, ChrifiAlaoui E, Andreone S, Poon KS et al. LXR directly regulates glycosphingolipid synthesis and affects human CD4+ T cell function. Proc Natl Acad Sci USA. 2021;118(21):e2017394118. DOI: 10.1073/pnas.2017394118. de la Aleja AG, Herrero C, Torres-Torresano M, Schiaf no MT, del Castillo A, Alonso B et al. Inhibition of LXR controls the polarization of human inflammatory macrophages through upregulation of MAFB. Cell Mol Life Sci. 2023;80(4):96. DOI: 10.1007/s00018-023-04745-4. Gerasimova EV, Popkova TV, Gerasimova DA, Markina YV, Kirichenko TV. Subclinical carotid atherosclerosis in patients with rheumatoid arthritis at low cardiovascular risk. Biomedicines. 2023;11(3):974. DOI: 10.3390/biomedicines11030974. Pašková U. Lipid profile and risks of cardiovascular diseases in conditions of rheumatoid arthritis. Ceska Slov Farm. 2019;68(6):219–28. PMID: 31906689. McGarry T, Hanlon MM, Marzaioli V, Cunningham CC, Krishna V, Murray K et al. Rheumatoid arthritis CD14+ monocytes display metabolic and inflammatory dysfunction, a phenotype that precedes clinical manifestation of disease. Clin Transl Immunology. 2021;10(1):e1237. DOI: 10.1002/cti2.1237. Murphy AJ, Akhtari M, Tolani S, Pagler T, Bijl N, Kuo CL et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest. 2011;121(10):4138–49. DOI: 10.1172/JCI57559. QuevedoAbeledo JC, SánchezPérez H, TejeraSegura B, de Armas-Rillo L, Armas-González E, Machado JD et al. Differences in capacity of high-density lipoprotein cholesterol efflux between patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(11):1590–6. DOI: 10.1002/acr.24407. Duan Y, Gong K, Xu S, Zhang F, Meng X, Han J. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther. 2022;7(1):265. DOI: 10.1038/s41392-022-01125-5. Dragoljevic D, Kraakman MJ, Nagareddy PR, Ngo D, Shihata W, Kammoun HL et al. Defective cholesterol metabolism in haematopoietic stem cells promotes monocyte-driven atherosclerosis in rheumatoid arthritis. Eur Heart J. 2018;39(23):2158–67. DOI: 10.1093/eurheartj/ehy119. Charles-Schoeman C, Wang J, Shahbazian A, Wilhalme H, Brook J, Kaeley GS et al. Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis. Rheumatol Int. 2023;43(6):1041–53. DOI: 10.1007/s00296-023-05285-7. Richter P, Cardoneanu A, Rezus C, Burlui AM, Rezus E. Non-traditional pro-inflammatory and pro-atherosclerotic risk factors related to systemic lupus erythematosus. Int J Mol Sci. 2022;23(20):12604. DOI: 10.3390/ijms232012604. McMahon M, Seto R, Skaggs BJ. Cardiovascular disease in sys-temic lupus erythematosus. Rheumatol Immunol Res. 2021;2(3):157–72. DOI: 10.2478/rir-2021-0022. Frostegård J. Systemic lupus erythematosus and cardiovascular disease. J Intern Med. 2023;293(1):48–62. DOI: 10.1111/joim.13557. Fang F, Xiao C, Li C, Liu X, Li S. Tuning macrophages for atherosclerosis treatment. Regen Biomater. 2022;10:rbac103. DOI: 10.1093/rb/rbacC103. Zhao L, Zhang Q, Feng Z, Zhang J, He F. Serum amyloid A-to-albumin ratio as a potential biomarker to predict the activity, severity, and poor prognosis of systemic lupus erythematosus. J Clin Lab Anal. 2022;36(3):e24282. DOI: 10.1002/jcla.24282. Shridas P, Tannock LR. Role of serum amyloid a in atherosclerosis. Curr Opin Lipidol. 2019;30(4):320–5. DOI: 10.1097/MOL.0000000000000616. Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci USA. 2008;105(34):12224–9. DOI: 10.1073/pnas.0802025105. Bauer R, Brüne B, Schmid T. Cholesterol metabolism in the regulation of inflammatory responses. Front Pharmacol. 2023;14:1121819. DOI: 10.3389/fphar.2023.1121819. Skaggs BJ, Hahn BH, Sahakian L, Grossman J, McMahon M. Dysfunctional, pro-inflammatory HDL directly upregu-lates monocyte PDGFRβ, chemotaxis and TNFα production. Clin Immunol. 2010;137(1):147–56. DOI: 10.1016/j.clim.2010.06.014. Ganjali S, Shirmohammadi L, Read MI, Sahebkar A. High-density lipoprotein functionality in systemic lupus erythematosus. Semin Arthritis Rheum. 2020;50(4):769–75. DOI: 10.1016/j.semarthrit.2020.05.011. Hardoňová M, Šiarnik P, Siváková M, Suchá B, Vlček M, Imrich R et al. Autonomic nervous system function in newly diagnosed multiple sclerosis: association with lipid levels and insulin resistance. Physiol Res. 2021;70(6):875–82. DOI: 10.33549/physiolres.934695. Pineda-Torra I, Siddique S, Waddington KE, Farrell R, Jury EC.Disrupted lipid metabolism in multiple sclerosis: a role for liver X receptors? Front Endocrinol (Lausanne). 2021;12:639757. DOI: 10.3389/fendo.2021.639757. Cozzani E, Rosa GM, Burlando M, Parodi A. Psoriasis as a cardiovascular risk factor: updates and algorithmic approach. G Ital Dermatol Venereol. 2018;153(5):659–65. DOI: 10.23736/S0392-0488.18.06040-6. Nowowiejska J, Baran A, Flisiak I. Aberrations in lipid expression and metabolism in psoriasis. Int J Mol Sci. 2021;22(12):6561. DOI: 10.3390/ijms22126561.